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Avidin is a glycoprotein from hen egg white that binds biotin with very high aﬃnity. Here we describe OXavidin, a product
containing aldehyde groups, obtained by ligand-assisted sugar oxidation of avidin by sodium periodate. OXavidin chemically
reacts with cellular and tissue proteins through Schiﬀ’s base formation thus residing in tissues for weeks while preserving the
biotin binding capacity. The long tissue residence of OXavidin as well as that of OXavidin/biotinylated agent complex occurs in
normal and neoplastic tissues and immunohistochemistry shows a strong and homogenous stromal localization. Once localized in
tissue/tumor, OXavidin becomes an “artiﬁcial receptor” for intravenous injected biotin allowing tumor targeting with biotinylated
therapeutics like radioisotopes or toxins. Moreover, present data also suggest that OXavidin might be useful for the homing of
biotinylated cells. Overall, OXavidin exhibits a remarkable potential for many diﬀerent therapeutic applications.
Copyright © 2009 Rita De Santis et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Selective targeting of diseased tissues has been a challenging
goal for decades. However, especially for cancer, no simple
solutionhasbeenfoundthatmightconstituteavalidalterna-
tive to surgery. Brachytherapy is currently being recognized
as an optimal way for delivering conformal radiotherapy to
inoperable tumors [1] or oligometastases [2]. Nevertheless,
current brachytherapy must rely on a wide armamentarium
ofdevicesincludingballoons[3],catheters[4],orpermanent
seeds [5] whose placement and accurate dosimetry imply
sophisticated and time consuming processes. Recently, a
novel pretargeted brachytherapy method, named Intraoper-
ative Avidination for Radionuclide Treatment-IART,h a s
been described in patients subjected to surgery for early
breast cancer to prevent local recurrences [6]. This approach
is based on the intraoperative injection of avidin in the
surgical margins surrounding the excised tumor followed
by the intravenous injection of radioactive biotin within the
subsequent 24 hours. Avidin is a basic glycoprotein of about
66kDa extracted from hen egg white known for its high
aﬃnity for biotin [7, 8]. It is composed of four subunits
of identical amino acid sequence, each of which can bind
one molecule of biotin. Glycosylation accounts for about
10% of its molecular weight with an average of four to
ﬁve mannose and three N-acetylglucosamine residues per
subunit [9]. The short blood and tissue half life of avidin
was previously reported [10, 11]. In the present study we
chemically oxidized the avidin sugars with sodium periodate
generating aldehyde groups which proved able to react with
tissue protein amino groups in vivo. To prevent damage to
thebiotinbindingsites,avidinoxidationwasperformedafter
saturationwiththelowaﬃnityligand4-hydroxyazobenzene-
2 -carboxylic acid (HABA) [12] which is easily removed at
the end of oxidation. Such product named OXavidin exhibits
the property to stably bind normal and neoplastic tissues
through Schiﬀ’s base formation. A proof of principle of
its use in highly eﬃcient brachytherapy and preliminary
data showing its capacity to bind biotinylated cells are here
reported.2 Journal of Biomedicine and Biotechnology
2.MaterialsandMethods
2.1. Periodate Oxidation of Avidin. Avidin (Tecnogen SpA,
Caserta, Italy) was incubated, at the ﬁnal concentration of 3-
4mg/mL,withdiﬀerent concentrations of sodium periodate
(NaIO4) (Sigma-Aldrich, St Louis, USA), in 100mM acetate
buﬀe ra tp H5 . 5f o r1h o u ra tr o o mt e m p e r a t u r e ,w i t h
or without a molar excess of 4-hydroxyazobenzene-2 -
carboxylic acid (HABA) (Sigma-Aldrich) obtaining OXa-
vidin (OXavidinHABA) or oxidized avidin, respectively. At
the end of incubation OXavidin was freed from HABA
and formulated, like avidin and oxidized avidin, in 100mM
acetate buﬀer, 150mM NaCl, pH 5.5, by diaﬁltration. The
number of aldehyde groups (CHO), generated on the
carbohydrate moieties by oxidation, was evaluated using
Purpald reagent (Sigma-Aldrich) and propionaldehyde as
standard. The biotin-DOTA (ST2210) [13] binding capacity
of OXavidin, oxidized avidin, and PEGylated avidin were
evaluatedbyHABAassayaccordingtostandardmethod[12].
2.2. Protein Radiolabeling. Radiolabeling of all proteins was
performed with 125I by IODO-GEN kit (Pierce, USA), before
periodate oxidation, since iodination reaction occurs at pH
7.5 at which intermolecular formation of Schiﬀ’s bases of
oxidized glycoproteins would occur. 125I-PEGavidin (hydra-
zone) was obtained by reacting 125I-oxidized avidin with a
molar excess of 10kDa PEG hydrazide (Nektar Therapeutics,
San Carlos, USA), in 100mM sodium acetate buﬀer pH
5.5, one hour at room temperature. After puriﬁcation by
size exclusion chromatography 125I-PEGavidin was found to
contain an average of 8PEG/avidin according to a known
method[14].ST2210(SigmaTau,Pomezia,Italy)waslabeled
with 111Indium according to standard method [13].
2.3. Immunohistochemistry. Avidin or OXavidin (50μg/
mouse) was injected into the muscle of one hind limb or into
MDA-MB-468 human breast carcinoma xenotransplanted
masses. Mice were sacriﬁced 48 hours after injection and
treated tissues ﬁxed and paraﬃn embedded. Staining of
serial sections was performed with HRP-conjugated rabbit
antiavidinantibody(GeneTex,Irvine,CA,USA),followedby
DAB substrate.
2.4. Animal Studies. 125I-radiolabeled avidins (native, oxi-
dized or OXavidin) were injected in one hind limb muscle at
the dose of 50μgi n1 5μl( 6×105–2×106 cpm/mouse). For
kinetic determinations, groups of mice were sacriﬁced at the
indicatedtimepointsandtheinjectedsites,nontargetorgans
and blood collected and weighted and radioactivity quanti-
ﬁed by gamma counter. For the intratissue administration,
datawereexpressedasthe%ofinjecteddose/100mgoftissue
(% ID/100mg) rather than % ID/g because the distribution
volume of the intramuscular injection was <1g of tissue.
For 111In-ST2210uptakemicewerepretreatedwithOXavidin
or relevant controls and then injected intravenously, at the
indicated time points, with 5μgo f111In-ST2210 (6–20 ×
106 cpm/mouse)in100μLofvehicle.Allmiceweresacriﬁced
by CO2 asphyxia 1 or 2 hours after 111In-ST2210 injection,
the preavidinated site, non target organs, and blood were
collected, weighted, and radioactivity quantiﬁed by gamma
counter. Data were expressed as % ID/g. The care and
husbandry of mice were in accordance with the European
Directive 86/609 and Italian legislation.
2.5. OXavidin Uptake of Biotinylated Cells. Green ﬂuorescent
protein (GFP) expressing B16 melanoma cells were kindly
provided by the Department of Oncology Sigma Tau SpA.
Biotinylation was performed with Sulfo-NHS-LC-Biotin kit
(Pierce).ChamberslidesLab-TechII(NangeNuncInt.Corp.
IL, USA) were prepared with COS7 cell (ATCC, MD, USA)
monolayer and then incubated with avidin or OXavidin
(7.2μg/mL in 100mM sodium acetate pH 5.5) 2 hours
at 4◦C, washed twice with PBS, and then incubated with
biotinylated or not biotinylated GFP-expressing B16 cells
(7 × 105/1.8cm 2), 1 hour at 4◦C. After two washings with
PBS, slides were evaluated by a Nikon microscope (Eclipse
80, Nikon) equipped with a digital camera DXM1200F and
cell uptake was evaluated as the average of nine independent
microscopic ﬁelds.
3. Results and Discussion
3.1. Avidin Derivatives with Improved Tissue Half Life. We
conﬁrmed that the tissue residence of avidin as well as
that of its not glycosylated analogue streptavidin [15]i s
very short with less than 1% ID/100 mg present 24 hours
after intramuscular injection in mice (Figure 1). Avidin,
although diﬀusing from the injected limb as streptavidin,
exhibits lower residence in blood and faster and higher liver
accumulation, as expected from its known pharmacokinetic
and biodistribution [11]. Streptavidin accumulates in the
kidney. Therefore, in an attempt to improve the tissue half
life of avidin, while reducing localization in non target
organs, we conjugated it to polyethylenglycol (PEG) which
is known to improve blood half life of proteins [16]. Taking
into account that avidin oligosaccharides are not essential
for biotin binding [8] and to minimize the possible steric
hindrance of PEG on the biotin binding sites, PEGylation
of avidin was performed at the carbohydrate moieties.
Avidinwasoxidizedwithsodiumperiodatetoobtainreactive
aldehyde groups (CHO) from mannose and glucosamine
pyranosidic rings, according to a known method commonly
usedtoconjugatesugarsorglycoproteinstoaminogroupsby
forming Schiﬀ’s bases, or to hydrazide forming hydrazone
[17]. To evaluate tissue residence, 125I-radiolabeled avidin,
PEGavidin, and its reaction intermediate oxidized avidin
exhibiting reactive CHO groups, all formulated at pH 5.5
to prevent intra/interprotein Schiﬀ’s base formation by
oxidized avidin, were intramuscularly injected in mice. At
suchacidicpH,CHOgroupsarereactiveonlywithhydrazino
groups (pKa of hydrazide = 2.6) but are substantially inert
against protein amino groups (pKa of protein amino groups
= 8-9) which are in the protonated NH3
+ status; at neutral
and higher pH, CHO groups react with protein amino
groups to form Schiﬀ’s bases. The amount of both avidin
and PEGavidin, measured after 24 hours, was less thanJournal of Biomedicine and Biotechnology 3
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Figure 1: Diﬀusion kinetic of 125I-labeled avidin or streptavidin injected in a limb and distribution in blood, liver, and kidney. At indicated
timepoints,miceweresacriﬁcedandtissuesamplesweightedandcountedinagamma-counter.Dataareexpressedas%ID/100mgoftissue.
Each point is the average of 5 mice. Bars represent standard deviation.
1.5% ID/100mg of tissue while, unexpectedly, the amount
of oxidized avidin was about 10 times higher (Figure 2).
To further investigate this result the intramuscular resi-
dence of oxidized avidin 1, 24, and 48 hours after injection
and its capacity to uptake, at the same time points, intra-
venously injected biotin (111In-radiolebeled biotinDOTA
ST2210) were measured. Data in Figure 3 show that, one
hour after injection, the amount of oxidized avidin in the
treated limb was higher than avidin and the diﬀerence
increased with time. In fact, avidin was almost undetectable
after 24 and 48 hours while oxidized avidin was about 17%
and 14% ID/100mg of tissue, respectively (Figure 3(a)). At
the ﬁrst hour, consistently with higher residence of oxidized
avidin compared to avidin in the treated limb, it was
observedalowerdistributionofoxidizedavidininnontarget
organs (Figures 3(b)–3(d)). The amount of both oxidized
avidin and avidin in non target organs, 24 and 48 hours
after their intramuscular injection, was comparable and in
any case below 0.2% ID/100 mg of tissue. These kinetic
data suggested that oxidized avidin could be employed for
targeted administration of biotinylated agents in a time
frame wider than that allowed by avidin. In fact, the uptake
of 111In-ST2210, intravenously injected 24 or 48 hours
after intramuscular avidin, was at least 10 times higher
in oxidized avidin-treated limb than in the avidin-treated
one (Figure 3(e)). Despite the higher amount of oxidized
avidin in the treated limb at 1 hour, a higher uptake of
111In-ST2210 was observed in the avidin-treated one. This
result was attributed to a lower biotin binding potency of
oxidized avidin compared to avidin as a consequence of
the expected oxidation damage of some tryptophan residues
which are known to be relevant to the avidin biological
activity [8]. On the other hand, at 1 hour, the distribution of
111In-ST2210 in non target organs was lower with oxidized
avidin compared to avidin, particularly for kidney and
liver, coherently with the fact that the higher stability of
oxidized avidin at the injection site results in a reduced
distribution and consequent biotin uptake in non target4 Journal of Biomedicine and Biotechnology
Table 1: Setting up production method of OXavidin.
NaIO4 mM CHO/Avidin molar ratio ± SD ST2210 binding % ± SD Tissue residence % ID/100mg ± SD
(N)( N)2 4 h o u r s ( N)1 w e e k ( N)
Avidin — <LoQ @100 2.2 ± 0.4 0.5 ± 0.1
(5) (7) (5)
Oxidized avidin
1 5.6 ± 0.8 77.2 ± 0.9 3.1 ± 0.7 0.16 ± 0.03
(5) (4) (1) (1)
5 7.5 ± 0.8 55.7 ± 2.2 6.3 ± 0.3 0.99 ± 0.25
(5) (4) (1) (1)
10 8.4 ± 1.0 50.9 ± 2.4 18.0 ± 2.5 9.7 ± 3.2
(6) (6) (4) (3)
20 11.5 ± 1.5∗ 49.1 ± 2.1 19.1 ± 2.0 11.4 ± 1.3
(7) (6) (4) (3)
40 10.9 ± 2.6 44.5 ± 0.9 NT NT
(5) (4)
+HABA
OXavidin
1 4.0 ± 0.8 99.0 ± 0.2 NT NT
(3) (3)
5 7.1 ± 1.6 95.0 ± 1.7 NT NT
(4) (3)
10 8.5 ± 1.3 86.3 ± 1.6∗∗ 16.2 ± 2.3 9.9 ± 1.3
(5) (3) (4) (4)
20 12.9 ± 2.3# 81.4 ± 1.0#∗∗ 18.7 ± 1.1 11.7 ± 1.7
(6) (4) (5) (5)
40 9.8 ± 1.9 73.0 ± 0.6 NT NT
(4) (3)
N: Number of independent experiments; SD: Standard Deviation; NT: Not tested.
@The experimental value of 97.4 ± 0.5% obtained with ST2210 compared to free biotin by HABA assay is assumed as 100% reference value for modiﬁed
avidins; ∗P <. 05 versus 10mM; #P <. 01 versus 10mM (One way Anova followed by Student-Newman-Keuls); ∗∗P <. 001 versus same without HABA
(Two-way Anova followed by Bonferroni).
organs (Figure 3(f)–3(h)). These data indicate that oxidized
avidin has a longer and more speciﬁc tissue residence than
avidin and suggest that oxidation might have reduced its
biotin binding capacity.
3.2. OXavidin Production and Biological Characterization. To
prevent oxidation damage of the biotin binding sites of
avidin, we attempted the occupancy of the sites with the
low-aﬃnity ligand 4-hydroxyazobenzene-2
 -carboxylic acid
(HABA) [12], before oxidation. Several reaction conditions
were tested showing that HABA-protected oxidization of
avidin (OXavidinHABA, named for simplicity OXavidin)
followed by removal of HABA and formulation at pH
5.5 (to prevent intra/inter-protein Schiﬀ’s bases) allows
the generation of a product that exhibits a number of
CHO groups similar to oxidized avidin and positively
correlating with tissue persistence measured 24 hours and
1 week after intramuscular injection. However, the bio-
logical activity of OXavidin in terms of ST2210 binding
was signiﬁcantly higher than that of oxidized avidin indi-
cating that occupation of the biotin binding sites with
HABA, during oxidation, is useful to preserve the protein
function (Table 1). Demonstration that the persistence of
OXavidin in injected tissues is due to its capacity to form
Schiﬀ’s bases with tissue proteins at physiological pH was
obtained by reducing aldehyde groups of OXavidin with
sodium cyanoborohydride. In fact, tissue residence of such
reduced OXavidin was similar to that of avidin (data not
shown).
Concerning tissue localization, a much stronger and
homogenous distribution of OXavidin compared to avidin,
24 hours after injection, was observed by immunohisto-
chemistry, both in normal tissues (Figures 4(a), 4(b)) and
in xenotransplanted human breast tumor masses (Figures
4(c), 4(d)). Tissue localization appeared to be in the stroma
surrounding cells. We postulated that such highly eﬃcient
and homogenous tissue localization of OXavidin could be
exploited to target radioactive biotin to tumors representing
an appealing brachytherapy method particularly for the
easiness of placement by a simple injection and for the
possibility to uncouple the administration of OXavidin with
that of radiolabeled biotin. In fact, based on OXavidin
tissue kinetic, its administration could be performed intra-
operatively/radiologically guided, followed by intravenous
radioactive biotin even several days after OXavidin tissue
pretargeting. This two-step brachytherapy approach could
be useful in those cases where patient condition or logistic
factors might otherwise discourage access to therapy.Journal of Biomedicine and Biotechnology 5
0
5
10
15
20
%
I
D
/
1
0
0
m
g
Avidin
PEGavidin
Oxidized avidin
P<. 0001
P<. 0001
15.95
1.47 1.25
NS
Figure 2: Tissue residence of avidin, PEGavidin, and oxidized
avidin. 125I-labeled avidin, PEGavidin, and oxidized avidin were
formulated in 100mM sodium acetate pH 5.5 and injected in
the limb muscle at the dose of 50μgi n1 5 μL/mouse. Mice were
sacriﬁced 24 hours after injection and tissue samples weighted and
countedinagamma-counter. Dataareexpressedas%ID/100mgof
tissue. Each point is the average of 5 mice. Bars represent standard
deviation. Student’s t test was used for statistical analysis. NS: Not
signiﬁcant.
Therefore, a mouse model was performed as a proof
of principle of such pretargeted brachytherapy. Mice were
injected in one hind limb with either avidin or OXavidin and
after 48 hours received intravenous 111In-ST2210. The mice
were sacriﬁced at the indicated time points and radioactivity
in the treated limb as well as in other non target organs
measured by gamma counter. The amount of 111In-ST2210
after 2 hours from intravenous injection was about 150
times higher in the OXavidin-treated tissue than in the
avidin-treated one (Figure 5(a)). Signiﬁcant diﬀerence in
radioactivity level persisted at the subsequent time points up
to 24 hours from 111In-ST2210 intravenous injection when
about 63 times more radioactivity was found in the tissue
treated with OXavidin compared to avidin. The distribution
of 111In-ST2210 in non target organs was similar for avidin
and OXavidin and at all time points below 0.2% ID/g
of spleen and liver and below 2.0% for kidney (Figures
5(b), 5(c), 5(d), resp.). The area under the curve (AUC)
of 111In-ST2210 distribution into the treated limb resulted
about 100 times that of avidin while AUCs of avidin and
OXavidininnontargetorganswereverysimilar.Presentdata
conﬁrm that OXavidin stably binds tissues and eﬃciently
uptakes radioactive biotin thus supporting its possible use
in an innovative form of pretargeted brachytherapy with
radiolabeled biotin like 90Y-ST2210.
For clinical applications where a delayed administra-
tion of the biotinylated therapeutic is not necessary, the
use of the OXavidin/biotinylated therapeutic preformed
complex is also possible. As shown in Figure 6,2 4h o u r s
after intramuscular injection, the avidin-biotinDOTA and
OXavidin-biotinDOTA complexes were about 5% and 24%
ID/100mg of tissue, respectively. The amount of the avidin-
biotinDOTA complex was about twice that of avidin and
this statistically signiﬁcant diﬀerence was expected as it was
previously described that the biotin engagement induces
conformational modiﬁcation of avidin increasing its tissue
residence most likely by enhancing sugar exposition and
nonspeciﬁc interaction [10]. This mechanism is unlikely
to occur for OXavidin-biotinDOTA complex as the avidin
oxidation replaces sugars with aldehyde groups responsi-
ble for tissue binding of both OXavidin and OXavidin-
biotinDOTA complex. One day after intramuscular injec-
tion, slightly higher binding of OXavidin compared to the
OXavidin-biotinDOTA complex was observed. One week
after injection, both avidin and avidin-biotinDOTA complex
were below 0.5% ID/100mg of tissue while the amount
of both OXavidin and OXavidin-biotinDOTA complex was
about 17% ID/100mg. It is to note that such highly eﬃcient
tissue delivery and residence of the OXavidin-biotinDOTA
complex would result in a very low amount of radioactivity
needed to deliver a biological eﬀective dose to a tumor
that would translate into signiﬁcant cost reduction of
brachytherapy and improved compliance of both hospital
personnel and patients.
The use of OXavidin for brachytherapy will oﬀer a
number of advantages compared to current brachytherapy
devices. In fact, the perfusion of a target tissue with OXa-
vidin, compared to current devices, will allow to conform
more easily the therapy to the tumor/organ shape, will
result in a more homogeneous interstitial distribution of the
therapeutic agent, and will allow to delay of several days
the administration of biotinylated therapeutics which might
be also fractionated in repeated doses. As OXavidin stably
links tissue proteins there will be no need to immobilize the
treated tissue as needed in current seeds brachytherapy, to
prevent migration of the seeds. Moreover, as most of the
injectedOXavidinbindsandresideswithinthetreatedtissue,
it will not be necessary to perform a “chasing step” with
biotinylated albumin to block biotin uptake in non target
organs as done in IART [6].
In order to evaluate the possible use of OXavidin to
uptake biotinylated agents larger in size than biotinDOTA,
avidin or OXavidin was added to a monolayer of COS7
cells grown on chamber slides and, after washings, the slides
were incubated with GFP-expressing B16 melanoma cells
both biotinylated and not biotinylated. Figure 7 shows that
1.25 ± 1.14 and 1.42 ± 1.16 B16 cells/ﬁeld were bound to
avidin- and OXavidin-treated COS7 slides, respectively. On
the other hand, 4.17 ± 2.44 and 45.75 ± 1.39 biotinylated
B16cells/ﬁeldwerecountedonavidin-andOXavidin-treated
COS7 slides, respectively. Overall, data indicate that this
cell-cell binding is OXavidin/biotin mediated and suggest
the possible use of OXavidin to uptake biotinylated cells in
treated tissues.
The use of an active, tissue binding compound like OXa-
vidin which, to our knowledge, has no precedent example in
pharmaceutical drugs might raise safety concerns. However,
it should be taken into consideration that present in vivo
studies indicate good tolerability as neither systemic clinical
signs nor histological lesions were observed in the animals6 Journal of Biomedicine and Biotechnology
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treated with OXavidin. Moreover, the formation of Schiﬀ’s
bases between oxidized sugars and protein amino groups is
a common event in vivo, leading to protein glycation [18]
and ﬁnally it is known that hundreds of oxidized proteins are
physiologically produced in the body as common products
of oxidative stress [19]. We believe that it will be possible
to employ OXavidin for highly eﬃcient and speciﬁc tissue
targeting of therapeutic agents like radioisotopes, drugs,
growth factors, plasmids, viral vectors, or cells for each of
which biotinylation protocols are available [20–22].
4. Conclusion
In summary, a novel reagent is described named OXavidin
that preserves the biotin binding capacity of avidin while
exhibiting the property to chemically link tissues. This
product is obtained by HABA-assisted oxidation of avidin.
The production method is very convenient because, in a
perspective of OXavidin industrial development, HABA is
a nontoxic ligand and, for its low aﬃnity, it can be easily
removed after oxidation. Overall in vitro and in vivo data
suggestthatOXavidinhasaremarkablepotentialforavariety
of therapeutic applications.
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